[BIO USA] 카지노 바카라 Biologics poised for capacity expansion with plant 6 ready to launch

[by Ji, Yong Jun] “The preparatory work for Plant 6 has been finalized, and operations are ready to proceed pending approval from the board of directors.”

카지노 바카라 Biologics President & CEO John Rim made this statement on June 17 (local time) during a press briefing at BIO USA 2025, held in Boston, USA. “Demand for contract development and manufacturing (CDMO) services in the biopharmaceutical sector is projected to remain strong, while contract manufacturing (CMO) outsourcing continues to show un upward trend,” Rim further stated. “The bidding process for the expansion of the Songdo 3rd Bio Campus in Incheon city is proceeding without complications.”

카지노 바카라 Biologics finalized the construction of Plant 5 in April, increasing its total production capacity (CAPA) to 784,000 liters. This achievement is regarded as the establishment of an infrastructure capable of meeting global demand for antibody-based biopharmaceutical manufacturing, positioning the company as the CDMO with the largest production capacity worldwide.

◇“Still insufficient”: Rationale behind ongoing CDMO expansion strategy

The expansion of 카지노 바카라 Biologics’ CDMO capacity is driven by the global pharmaceutical industry’s strategic shift toward new treatment modalities. According to President John Rim, this includes a growing demand for antibody-centered pipelines, such as antibody-drug conjugates (ADCs), treatments for autoimmune diseases, and anticancer therapies, fueled by both the recent expansion of indications for blockbuster drugs and the continuous development of novel drug candidates. Rim further explained that, due to the cautious approach of global pharmaceutical firms towards building their own manufacturing facilities, reliance on CMO outsourcing is expected to increase. Since its founding, 카지노 바카라 Biologics has accumulated a total order volume of USD 18.7 billion (approximately KRW 25.6 trillion).

카지노 바카라 Biologics’ decision to expand its production capacity is viewed as a strategic initiative aimed at strengthening its position in the global CDMO market and preemptively responding to demand for next-generation modalities, rather than simply increasing output. Given the cautious stance of global pharmaceutical companies toward investing in their own manufacturing facilities, the company’s expansion strategy underscores its intent to further solidify its competitiveness as a CDMO company. “Orders are progressing well, and demand has, in fact, increased as antibody-based new drugs expand into areas like the nervous system and anti-aging,” Rim emphasized. “This capacity expansion does not constitute an oversupply.”

카지노 바카라 Biologics aims to expand its production infrastructure to a total of eight plants in the 2nd Bio Campus by 2032, targeting a cumulative capacity of 1.324 million liters. Concurrently, the company is considering the development of a 3rd Bio Campus by participating in the bidding process for the 11th site in Songdo, Incheon, to secure additional manufacturing facilities. This strategy initiative is designed to address rising global demand while maximizing synergies with the existing 1st and 2nd Bio Campuses, thereby securing economic feasibility through integration effects.

◇“The future is like a battle for preempting next-generation modalities”

카지노 바카라 Biologics intends to proactively respond to the anticipated growth of emerging treatment modalities. The company’s objective is to offer a diversified range of services by expanding its technological capabilities to include gene therapy such as ADCs, multi-specific antibodies, and adeno-associated viruses (AAV).

카지노 바카라 Biologics is already providing end-to-end support, from process development to GMP-compliant production, through its dedicated four-story facility for ADC-only production, which commenced operations in March. Notably, the facility not only handles the complete drug substance (DS) manufacturing process, including antibody production, payload synthesis, and linker conjugation, essential for ADC development, but also raised its technological capabilities to the extent that it can complete DS production within just 12.5 months from cell line development.

◇Transformed into a ‘pure CDMO’ through spin-off… Strengthening global reach

카지노 바카라 Biologics recently addressed concerns related to a ‘conflict of interest’ stemming from its biosimilar subsidiary, 카지노 바카라 Bioepis. By deciding to separate from 카지노 바카라 Bioepis, the company has reinforced its positioning as a ‘pure CDMO company.’ Although 카지노 바카라 Biologics has maintained a formal ‘firewall’ between the two entities, it was reported that some clients perceived the companies as a ‘single entity,’ leading to concerns raised by 카지노 바카라 Bioepis.

“Through this separation, we have achieved a completed disengagement from 카지노 바카라 Bioepis, enabling us to concentrate more fully on our core CDMO business,” Rim stated. “This move will unlock the ‘hidden value’ of our operations by allowing each company’s corporate value to be independently and accurately assessed,” he added.

Leveraging its global network of offices, 카지노 바카라 Biologics has expanded its client base for contract orders. With sales offices established in New Jersey and Boston, the company currently serves 17 of the world’s top 20 pharmaceutical firms. In a move to strengthen its presence in the Asian market, 카지노 바카라 Biologics opened an additional sales office in Tokyo, Japan, earlier this year, thereby increasing its regional customer engagement.

“We will continue to participate in various academic conferences, including the ‘BIO International Convention (BIO USA)’, to broaden our contact points with global clients,” expressed Rim. “We also intend to further reinforce our efforts to secure new orders,” he added.